- Why in news
- On 17 September 2026 the Health Ministry announced an advisory dated 16 September 2026 to States and UTs on regulating stem cell therapy, following the Supreme Court's 30 January 2026 judgment in Yash Charitable Trust v. Union of India.
- What it is
- Stem cell research and therapy in India is governed by the National Guidelines for Stem Cell Research, 2017 (ICMR and DBT), along with drugs and clinical establishment rules. Stem cell therapy is treated as an experimental intervention unless the Ministry approves the indication. The Clinical Establishments Act, 2010 regulates registration and standards of clinical establishments in States that have adopted it.
- Advisory scope
- Issued on 16 September 2026 to States and UTs that have adopted the Clinical Establishments Act, 2010.
- Standard care rule
- Stem cell therapy is allowed as routine standard care only for indications on the Ministry-approved list.
- Autism
- Any therapeutic use of stem cells in autism stays restricted to approved clinical trials under the 2017 National Guidelines issued by ICMR and DBT.
- Penalties
- Non-compliance can mean professional misconduct under Regulation 7.22 of the IMC Regulations, 2002, and action under Sections 32 and 40 of the Clinical Establishments Act (cancellation of registration and penalty).
Don’t confuse with ICMR vs DBT: ICMR is the apex body for biomedical research under the Health Ministry; DBT is under the Ministry of Science and Technology. The 2017 stem cell guidelines were issued jointly by both.
Don’t confuse with NMC vs State Medical Councils: The NMC sets national standards and issued an advisory. State Medical Councils examine individual cases of alleged misconduct and take disciplinary action.
Laws, judgments and statutory bodies: 30 Prelims questions since 2013 (what the law says, who chairs, legal basis). In Mains, 44 news-triggered questions, most in GS2, asking for provisions and challenges.
Why it matters
- Protects patients, especially families of children with autism, from unproven and costly treatments.
- Aligns regulation with a Supreme Court judgment and gives its directions an enforcement route.
Problems
- The Clinical Establishments Act applies only in States that adopted it, so enforcement is uneven.
- Unproven clinics and online advertising are hard to monitor, and desperate patients remain vulnerable.
Way forward
- Strengthen State and District regulatory authorities and monitor advertising and promotion.
- Expand approved clinical trials and publish clear, updated lists of approved indications.
Put in your answer
Supreme Court judgment: Yash Charitable Trust v. Union of India (30 January 2026) held that non-compliance with the stem cell framework must attract consequences, including professional misconduct and action under the Clinical Establishments Act.
National Guidelines for Stem Cell Research, 2017: ICMR-DBT guidelines are the base framework for stem cell research and therapy; autism use is limited to approved trials under them.
- 2017Mains GS3 · Q6Describe stem cell therapy and its advantages over other treatments.
- 2026Mains GS4 · Q2Should DM use untested mineral remedy on tribe? Discuss ethics.
- 2024Mains GS4 · Q12Ethical pressures to expedite drug trials during viral outbreak.
UPSC’s own questions that come close to this issue, from our Prelims and Mains banks.
Prelims practice · Statements
Ours, not from a UPSC paper
Consider the following statements:
- 1.The National Guidelines for Stem Cell Research, 2017 were issued jointly by the Indian Council of Medical Research and the Department of Biotechnology.
- 2.Under the Health Ministry's September 2026 advisory, stem cell therapy may be offered as routine standard care only for indications on the Ministry-approved list.
- 3.The Health Ministry's advisory on stem cell therapy is addressed to all States and Union Territories, whether or not they have adopted the Clinical Establishments (Registration and Regulation) Act, 2010.
Which of the statements given above is/are correct?
True or false?
1 of 7
Statements the way Prelims prints them. Say first, then see the fact.
1.The advisory is addressed to all States and UTs that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010.
True. The advisory targets States and UTs that have adopted the 2010 Act.
2.Under the advisory, stem cell therapy may be offered as routine standard care for any condition once a clinical establishment is registered.
False. Only for indications on the Ministry-approved list.
3.The therapeutic use of stem cells in autism is restricted to approved clinical trials.
True. Autism use stays within approved clinical trials.
4.The National Guidelines for Stem Cell Research, 2017 were issued jointly by ICMR and the Department of Science and Technology.
False. They were issued by ICMR and the Department of Biotechnology (DBT).
5.Sections 32 and 40 of the Clinical Establishments Act, 2010, cited in the advisory, provide for cancellation of registration and penalty.
True. These sections cover cancellation of registration and penalty.
6.The NMC advisory directs State Medical Councils to examine alleged violations and act against practitioners after due process.
True. State Medical Councils examine cases and take disciplinary action after due process.
7.The Clinical Establishments Act, 2010 applies automatically to all States without any need for adoption.
False. It applies in Union Territories and in States that adopted it (it was enacted under Article 252); it is not automatic for all States.
Written by us from the release, not by UPSC; checked by a second model.
Mains practice
15 marks · 250 words
The Union Health Ministry has issued an advisory to States and UTs on regulating stem cell therapy, following the Supreme Court's January 2026 judgment in Yash Charitable Trust v. Union of India. Discuss the existing legal and regulatory framework governing stem cell therapy in India and examine the challenges in enforcing it. Suggest a way forward.
Worth revising until Prelims 2028: most news questions come within two years of the event.